Search research articles
Contact Us
Filters
Showing results (121-130 of 336) with videos related to
Page
of 34
Sort By:
Hemasphere
|
April 21, 2020
Reducing Bureaucracy in Clinical Research: A Call for Action
John Gribben, Elizabeth Macintyre, Pieter Sonneveld, et al.
BMC Cancer
|
August 13, 2024
Knowledge, skills, and confidence gaps impacting treatment decision making in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma: a quantitative survey study in France, Germany, and the United States
Sophie Peloquin, Florence Cymbalista, Martin Dreyling, et al.
Haematologica
|
August 28, 2015
Precision medicine in diffuse large B-cell lymphoma: hitting the target
Joost S Vermaat, Steven T Pals, Anas Younes, et al.
Leukemia & Lymphoma
|
April 7, 2009
A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study
Oliver Weigert, Eckhart Weidmann, Rudolf Mueck, et al.
Leukemia & Lymphoma
|
September 24, 2016
Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy
Mark D Danese, Robert I Griffiths, Michelle L Gleeson, et al.
Genes, Chromosomes & Cancer
|
November 1, 2005
Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma
Grit Hutter, Miriam Scheubner, Yvonne Zimmermann, et al.
Cancer
|
August 1, 2006
Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group
Christina Nickenig, Martin Dreyling, Eva Hoster, et al.
European Journal of Haematology
|
January 6, 2025
SARS-COV-2 Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab in Haematological, Immunocompromised Patients in the Omicron Era
Manuela A Hoechstetter, Eva-Maria Hollwich, Doris Illner, et al.
Journal of Bone Oncology
|
October 21, 2020
Primary bone lymphoma: Clinical presentation and therapeutic considerations
Annika Müller, Martin Dreyling, Falk Roeder, et al.
Haematologica
|
July 2, 2011
Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases
Ralf Trappe, Heiner Zimmermann, Susanne Fink, et al.
Page
of 34
Search research articles
Search
Showing results (121-130 of 336) with videos related to
Sort By:
Page
of 34
Hemasphere
|
April 21, 2020
Reducing Bureaucracy in Clinical Research: A Call for Action
John Gribben, Elizabeth Macintyre, Pieter Sonneveld, et al.
BMC Cancer
|
August 13, 2024
Knowledge, skills, and confidence gaps impacting treatment decision making in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma: a quantitative survey study in France, Germany, and the United States
Sophie Peloquin, Florence Cymbalista, Martin Dreyling, et al.
Haematologica
|
August 28, 2015
Precision medicine in diffuse large B-cell lymphoma: hitting the target
Joost S Vermaat, Steven T Pals, Anas Younes, et al.
Leukemia & Lymphoma
|
April 7, 2009
A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study
Oliver Weigert, Eckhart Weidmann, Rudolf Mueck, et al.
Leukemia & Lymphoma
|
September 24, 2016
Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy
Mark D Danese, Robert I Griffiths, Michelle L Gleeson, et al.
Genes, Chromosomes & Cancer
|
November 1, 2005
Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma
Grit Hutter, Miriam Scheubner, Yvonne Zimmermann, et al.
Cancer
|
August 1, 2006
Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group
Christina Nickenig, Martin Dreyling, Eva Hoster, et al.
European Journal of Haematology
|
January 6, 2025
SARS-COV-2 Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab in Haematological, Immunocompromised Patients in the Omicron Era
Manuela A Hoechstetter, Eva-Maria Hollwich, Doris Illner, et al.
Journal of Bone Oncology
|
October 21, 2020
Primary bone lymphoma: Clinical presentation and therapeutic considerations
Annika Müller, Martin Dreyling, Falk Roeder, et al.
Haematologica
|
July 2, 2011
Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases
Ralf Trappe, Heiner Zimmermann, Susanne Fink, et al.
Page
of 34